BiotechTube

Hetrombopag + Matching placebo

Phase 3Withdrawn
0 watching 0 views this weekπŸ“ˆ Rising
77
Hype Score

Development Stage

βœ“
Pre-clinical
βœ“
Phase 1
βœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chemotherapy-Induced Thrombocytopenia

Conditions

Chemotherapy-Induced Thrombocytopenia

Trial Timeline

Apr 15, 2022 β†’ Dec 15, 2025

NCT ID
NCT05261646

About Hetrombopag + Matching placebo

Hetrombopag + Matching placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Chemotherapy-Induced Thrombocytopenia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05261646. Target conditions include Chemotherapy-Induced Thrombocytopenia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05261646Phase 3Withdrawn

Competing Products

20 competing products in Chemotherapy-Induced Thrombocytopenia

See all competitors
ProductCompanyStageHype Score
SON-080Sonnet BioTherapeuticsPhase 1/2
36
GranisetronKyowa KirinPhase 3
77
ONO-7746Ono PharmaceuticalPhase 1
33
ONO-2910 + PlaceboOno PharmaceuticalPhase 2
52
PROCRIT 40,000 IU QW + PlaceboJohnson & JohnsonPhase 2
52
Hetrombopag Olamine + Hetrombopag Olamine οΌ›Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 2
52
Hetrombopag + Hetrombopag plus Placebo + PlaceboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag + PlaceboJiangsu Hengrui MedicinePhase 3
77
Fosaprepitant dimeglumine + Fosaprepitant Placebo + Dexamethasone + Ondansetron + Dexamethasone Placebo + Ondansetron Placebo + Rescue TherapyMerckPhase 3
77
FosaprepitantMerckPhase 2
52
Fosaprepitant + Placebo for fosaprepitant + Ondansetron + Dexamethasone + 5-HT3 antagonistMerckPhase 3
77
Fosaprepitant + Dexamethasone + 5HT3MerckPhase 2
52
aprepitant + Comparator: Placebo to aprepitant + dexamethasone + granisetron + dexamethasoneMerckPhase 3
77
aprepitant + Comparator: ondansetron + Comparator: dexamethasone + Comparator: fosaprepitant dimeglumine + Comparator; Placebo (unspecified) + Comparator; Placebo (unspecified)MerckPhase 3
77
EMENDMerckPre-clinical
23
Fosaprepitant Dimeglumine + 5-HT3 antagonist + DexamethasoneMerckApproved
85
ondansetron clinical trial formulation + ondansetron marketed formulationMerckPhase 1
33
Aprepitant + Palonosetron + DexamethasoneMerckPhase 2
52
Fosaprepitant 150 mg + Aprepitant 165 mg + Aprepitant 250 mg + Dexamethasone (12-8-16-16 mg) + Dexamethasone (12-8-8-16 mg) + Ondansetron + MK0999MerckPhase 1
33

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85